Sandoz Secures Settlement for Inflating Drug Prices — $400 Million
RedMap Risk Score
80/100
CRITICAL RISK
Risk Signal Summary
New York Attorney General Letitia James secured a $400 million settlement from Sandoz Inc. for their role in a scheme to inflate generic drug prices. The settlement follows lawsuits against multiple pharmaceutical companies involved in illegal price-fixing agreements.
Why This Matters
Governance and compliance anomalies in organizations managing public funds or charitable assets directly affect donors, beneficiaries, and taxpayers. The risk indicators identified in this report warrant further scrutiny by regulators, donors, and oversight bodies.
Create a free account
Unlimited access to all articles · No daily limit
No credit card · Instant access
Multiple related entities detected
🔒 Sandoz Inc. and Fougera Pharmaceuticals Inc. has potential risk indicators with connected organizations. Unlock full network analysis.
Sign up free to unlock →Disclaimer: This report identifies risk indicators and unusual financial patterns based on publicly available IRS Form 990 data and government enforcement records. It does not assert fraud, criminal conduct, or legal violations. All findings are for informational purposes only and should not be construed as legal or financial advice.
Share this finding
You just analyzed Sandoz Inc. and Fougera Pharmaceuticals Inc. — Risk Score 80/100, $400.0M involved. Share this with your network.
Post text is pre-formatted for maximum reach — you can edit before posting.
Discover more risk signals across the USA.